Home > News > Metabolic Control in Children with Type 1 Diabetes
Diabetes
Read Time: 2 mins

Metabolic Control in Children with Type 1 Diabetes

Published Online: June 6th 2011 European Endocrinology, 2010; 6:35-8; DOI: http://doi.org/10.17925/EE.2010.06.00.35
Authors: Joachim Rosenbauer, Tilman Rohrer, Ina Knerr, Axel Dost, Eva M Gerstl, Reinhard W Holl
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Abstract
Since 1993, diabetes therapy has been intensified in several ways: insulin analogues have been introduced and insulin pump therapy has been established as a standard therapy in paediatric diabetology, improved devices for self-control have been developed and continuous glucose measurement has been introduced in diabetes monitoring. These technical improvements have been accompanied by new training programmes for children and adolescents with diabetes and their relatives. These programmes aim to empower the patient and his or her family to self-manage diabetes and not to depend on professional advice, as was previously the case. Interdisciplinary teams have been established to train and support families in the management of diabetes. There was a big hope that these improvements would result in a significantly better metabolic situation. This article reviews the changes in diabetes treatment and the outcomes over the last few years: the average glycated haemoglobin (HbA1c) levels fell only marginally, although insulin therapy was intensified considerably; the insulin dose increased and resulted in weight gain. However, the proportion of patients with good metabolic control increased and the proportion of patients with bad metabolic control dropped. Intensifying therapy also resulted in fewer hypoglycaemic episodes, particularly if insulin pumps were used. As well as echnical improvements, it is important to address the patient’s situation, problems and needs, and it is necessary to individually tailor diabetes therapy. The new devices and training programmes will help us to reach this goal and eventually reduce the rate of diabetic complications.

Keywords
Type 1 diabetes in children, metabolic control, intensified conventional insulin therapy (ICT), insulin pump (CSII), multiple-dose injections (MDIs), insulin analogues

Disclosure: The authors have no conflicts of interest to declare.
Acknowledgements: The DPV-Initiative is supported by the German Federal Ministry of Health, Novo Nordisk Pharma GmbH, Germany, the Dr Bürger-Büsing Foundation and the German Diabetes Foundation, and the German Research Foundation, the German Medical Association and the National Action Forum Against Diabetes Mellitus (NAFDM). Formed in 2008, the DPV-Initiative is part of the German Diabetes Competence Network. The sponsors were not involved in this particular investigation at any time. A list of the centres collaborating in the DPV-Initiative can be accessed at dpv.mathematik.uni-ulm.de
Received: 24 June 2009 Accepted: 5 October 2009 Citation: European Endocrinology, 2010;6(1):35–38
Correspondence: Axel Dost, Department of Paediatrics, Friedrich Schiller University of Jena, Kochstrasse 2, D-07740 Jena, Germany. E: Axel.Dost@med.uni-jena.de

Article:

In 1993, the Diabetes Control and Complication Trial (DCCT) clearly showed that intensified diabetes treatment improves clinical outcome and reduces long-term complications in patients with type 1 diabetes. We also learned from the DCCT that metabolic control needs to be optimised from the diagnosis of diabetes to delay or at least slow the progression of diabetic retinopathy, nephropathy and neuropathy.1 Children with diabetes onset in early life and therefore a lengthy diabetes duration are at particularly high risk of diabetic micro- and macrovascular complications.

In 1993, the Diabetes Control and Complication Trial (DCCT) clearly showed that intensified diabetes treatment improves clinical outcome and reduces long-term complications in patients with type 1 diabetes. We also learned from the DCCT that metabolic control needs to be optimised from the diagnosis of diabetes to delay or at least slow the progression of diabetic retinopathy, nephropathy and neuropathy.1 Children with diabetes onset in early life and therefore a lengthy diabetes duration are at particularly high risk of diabetic micro- and macrovascular complications. Therefore, paediatric diabetologists in particular have to strive for normoglycaemia in their patients.

Since the DCCT, more than a decade of improvements in diabetes management has passed. New treatment options are available, such as analogue insulins and insulin pumps, continuous subcutaneous insulin infusion (CSII), better and easier-to-handle devices for self blood glucose measurements, continuous glucose monitoring (CGM) and intensified diabetes education based on standardised evaluated training programmes. Treatment of children and adolescents with diabetes affects not only patients and their needs, but also parents, siblings, grandparents and, in adolescents, peer group. Therefore, modern paediatric diabetes treatment can only be achieved by a multidisciplinary team including diabetes nurses, dieticians, psychologists and paediatric diabetologists as recommended by the International Society for Pediatric and Adolescent Diabetes (ISPAD).2 Most paediatric diabetes centres have adopted these guidelines and work accordingly. ISPAD recommends a glycated haemoglobin (HbA1c) level <7.5% (DCCT standard) as the metabolic goal. This level is slightly higher than the 7% recommended by the DCCT, but takes into account that there is a higher risk of hypoglycaemia in smaller children and that metabolic control deteriorates during puberty.3 A significant improvement in metabolic control is expected after 16 years of intensified diabetes management. This article reviews the changes in diabetes treatment and various clinical outcomes.

Changes in Therapy

At the beginning of the 1990s, conventional insulin therapy with two daily injections of an individualised mixture of rapid- and intermediateacting insulins was the standard therapy in paediatric diabetology. Meanwhile, insulin regimens have been intensified: multiple-dose injections (MDI), intensified conventional therapy (ICT) or CSII.

In a Western Australian cohort of children with diabetes, the rate of CT decreased from 96% in 1992 to 60.2% in 2002. In 1992, 2.3% of the patients were treated with MDI; this number went up to 17.1% in 2002. The number of patients on CSII increased from 0.9% in 2000 to 8.2% in 2002, and the use of analogue insulins increased from 1.4% in 1997 to 36% in 2002.4 In 2000, 57.8% of Danish children with type 1 diabetes <18 years of age were on two injections or fewer per day, 25.9% were on three injections per day and 16.3% were on four or more injections per day. In 2000–2005, >70% were on two injections or fewer per day. The use of both long- and short-acting analogues increased in this time period.5 Similarly, in the paediatric diabetes centre in Hannover, the rate of CT decreased from about 90% in 1986 to approximately 1% in 2006, whereas ICT increased from approximately 10% in 1986 to more than 80% in 1999 and fell in the following years due to a significant increase in the use of CSII.6

The majority of paediatric diabetes centres in Germany and Austria collaborated in the Diabetes Prospective Documentation (DPV) quality initiative. The data are locally generated, documented and transmitted in anonymous form to the University of Ulm for central evaluation and analysis.7 By September 2008, records of 44,693 patients <18 years of age with type 1 diabetes were documented in this database. DPV started in 1994; by that time almost 50% of children were being treated with conventional insulin therapy. At the time of the latest survey, only a negligible number of the patients were still on CT, but use of MDI and CSII had increased significantly. From 1996 to 2007, the use of analogue insulins increased significantly in all age groups, not only in long-term therapy but also at the onset of diabetes8 (see Figures 1 and 2).

Insulin Dosage

In the Western Australian investigation from 1992 until 2002, the average daily insulin dose rose significantly from 0.83Uxkg-1xd-1 to 1.00Uxkg-1xd-1.4 During the decade from 1995 to 2005, the insulin dosage increased from 0.85Uxkg-1xd-1 in 1995 to 0.98Uxkg-1xd-1 in 1998 and to 1.0 Uxkg-1xd-1 in the patients of the Hvidoere group.9 Insulin dosage was not related to metabolic control in paediatric diabetes centres in Northern Ireland,10 whereas a significant relation between HbA1c and insulin dosage was reported for young people in Scotland.11 In the German/Austrian patients using rapid- or long-acting insulin analogues, the daily dosage was 5–11% higher than in patients of comparable age who used regular human insulin and neutral protamine Hagedorn (NPH) or zinc insulin. The daily insulin dose increases from early childhood (0.67IU/kg) to adolescence (0.93IU/kg) and decreases towards adulthood (0.7IU/kg). Girls needed the highest insulin dose at 12 years of age; boys at 14 years of age. Patients receiving CSII had a lower total insulin requirement12 and lower pre-prandial insulin boli than children of the same age with MDI. Girls needed more insulin boli and higher insulin doses per 10–12g carbohydrates than boys.13 Insulin requirements were significantly lower in the CSII groups compared with MDI in a meta-analysis of investigations on adolescent patients with type 1 diabetes.14

Metabolic Control

Dorchy et al. showed that good metabolic control can be achieved using a regime of two daily injections of an individualised mixture of rapid- and intermediate-acting insulins.15 In Western Australian children, HbA1c fell from 10.9 to 8.1% from 1992 to 2002; the improvement in metabolic control was associated with higher insulin dosage (0.83Uxkg-1xd-1 in 1992 and 1.0Uxkg-1xd-1 in 2002) and an increased rate of severe hypoglycaemia (7.8 per 100 patient-years in 1992 and 16.6 per 100 patient-years in 2002).4 In Hannover, the rate of patients with a good HbA1c level <7.5% increased from 22 to 55%, whereas the rate of bad metabolic control (HbA1c >9%) has dropped from 35 to <10% within the last 20 years.6 From 1996 to 2006, a significant decrease in HbA1c was shown in the Danish Childhood Diabetes Registry. HbA1c was affected by the number of blood glucose measurements, but tended to be higher in the children using analogue insulins compared with non-users.5

However, the Hvidoere group of 21 paediatric diabetes centres from 17 countries failed to show a significant fall in HbA1c from 1995 to 2005, despite intensified insulin therapy and an increase in insulin dosage.91c levels remained basically unchanged (1995 8.6%, 1998 8.7%, 2005 8.6%). In 2005, the lowest HbA1c was achieved in the group with free mixed insulin twice daily (7.9 versus 8.6% twice daily pre-mix, 8.2% thrice daily, 8.2% MDI and 8.1% CSII). The quality of metabolic control differed significantly between the centres; these differences persisted throughout the decade of observation.9,16

In Germany and Austria, intensifying diabetes management resulted in a slight but significant reduction by -0.2% in overall HbA1c levels: treatment period 1994–1998 HbA1c (DCCT standard) 8.1%, 1999–2002 8%, 2003–2006 7.9%, 2007–2008 7.9%. However, in the decade from 1994 to 2004, the patients with good metabolic control (HbA1c <7.5%) increased from 25 to 45%, whereas the percentage of patients with bad metabolic control (HbA1c >9%) fell from 40 to 15%.17 HbA1c increased with age (see Figure 3), diabetes duration and female gender (female 8.2% versus male 7.9%). HbA1c levels were slightly lower during the summer and significantly higher in children with a migration background (8.3% versus 8% German/Austrian). In 2005, 87% of the patients were treated with ICT or CSII, 13% with CT. HbA1c was lower in the CT cohort (8.2% versus 8.3% ICT/CSII), and the children receiving CT were on average 1.5 years younger and slimmer.

HbA1c also depends on the type of insulin used: patients using analogue insulins had higher HbA1c levels (8.2% versus 8.1% for shortacting analogues versus regular insulin and 8.4% versus 8% for longacting analogues versus NPH or zinc suspensions).13 HbA1c was significantly lower in patients on CSII during the first year of the new regimen, but rose to the same level as patients on MDI after three years. Diabetic ketoacidosis was significant lower in CSII treatment compared with MDI.18 HbA1c was significantly reduced in adolescents receiving CSII in a meta-analysis of three randomised controlled trials.14

Hypoglycaemia

The rate of hypoglycaemia increased with the intensity of insulin therapy and improvement of metabolic control: in Western Australia from 7.8 to 16.6 per 100 patient-years (1992–2002).

According to a meta-analysis of three studies, the rate of severe hypoglycaemia in children with type 1 diabetes was low. Only three events were recorded for patients in the CSII groups, and six events in the MDI groups, taking all trials together.14 However, using CGM hypoglycaemia prevalence was 10.1% and highest between 4:00 and 7:30am. Nocturnal hypoglycaemia was prolonged and mostly asymptomatic. The risk of nocturnal hypoglycaemia was associated with decreasing age, increased insulin dose, insulin regimen (with a two-injection regimen having a higher risk) and increased body mass index standard deviation score (BMI SDS).19 In the centres of the Hvidoere group, the lowest rate of hypoglycaemia occurred in the centres with the best metabolic control and decreased with impairment of metabolic control; this trend was stable from 1995 to 1998.16 The rate of hypoglycaemia seems to depend on the therapeutic regime: long-acting analogue insulins (glargine or detemir) do not seem to reduce the risk of severe hypoglycaemia compared with NPH insulin.20

A meta-analysis of 15 randomised trials showed that adolescent and adult patients with type 1 diabetes using CSII had non-significantly fewer minor hypoglycaemic episodes compared with MDI, whereas children on pump therapy had significantly more episodes.21 By contrast, the severe hypoglycaemia rate was markedly reduced during CSII compared with MDI, particularly in older subjects. The greatest reduction in severe hypoglycaemia occurred in those subjects with the highest initial hypoglycaemia frequency.22 In children from Germany and Austria, changing therapy from MDI to CSII was followed by a drop of hypoglycaemia from 25.1 to 17.9 per 100 patient-years.18 After changing to short-acting analogue insulins, the reduction of severe hypoglycaemia with (6.1/100 patient-years) and without coma (6.2/100 patient-years) was significant. After changing to long-acting analogues the rate of severe hypoglycaemia without coma dropped significantly.8

These data are supported by Pickup and Renard; in their investigation pump therapy reduced the average risk of severe hypoglycaemia in children with diabetes and adolescents by 66–79%.20 In the Danish Childhood Diabetes Registry, there was a negative association between severe hypoglycaemic events and the HbA1c level: in patients with HbA1c of 8–10% the rate of severe hypoglycaemia increased from 7.4 to 10.7%, whereas there was a decrease from 12.2 to 7.9% in the patients with HbA1c levels of 6–8%.5

Bodyweight

Bodyweight is significantly increased in children and adolescents with type 1 diabetes in Germany and Austria. During puberty, girls with diabetes are particularly at risk of increased bodyweight (16.6%) and obesity (11.2%).23 These findings do not seem to be specific for Germany and Austria, but are confirmed in several studies: in the Hvidoere group, the increase in the BMI of children with diabetes was much faster during adolescence compared with healthy children, especially in females.24 In UK children with type 1 diabetes, BMI SDS was also significantly elevated: in Scotland BMI SDS was 0.61 for boys and 0.57 for girls12 and in Northern Ireland BMI SDS was 0.85 for all paediatric patients.11 Australian children with type 1 diabetes had elevated BMI scores compared with non-diabetic controls; the patients in the upper quartile for BMI SDS were younger and had higher HbA1c levels and a shorter diabetes duration.25

There is a clear link between intensified insulin treatment and increased weight gain.23 In patients using ICT or CSII, BMI SDS was higher (0.52 and 0.56, respectively) compared with the patients on CT (BMI SDS 0.42).11 In Belgian children, BMI was significantly higher in girls and in adolescents on four daily injections compared with those on two injections.15 An increase in insulin dosage and injections was associated with an increase in BMI in the children of the Hvidoere study.16 BMI SDS was slightly, but significantly, higher in patients treated with either short- or long-acting insulin analogues compared with regular and NPH insulin.8

Although insulin dosage is lower using CSII, there was no significant effect on BMI in German/Austrian children after three years of treatment: BMI SDS CSII 0.57 versus MDI 0.56.18 However, children with type 1 diabetes with insulin resistance based on daily insulin dose per weight are not overweight to a greater extent than insulin-sensitive children with type 1 diabetes.26

Conclusion

During the last 15–20 years, diabetes therapy has been highly intensified in several ways. The use of new insulins or CSII did not lead to a significant fall in average HbA1c levels, but the number of paediatric patients with good metabolic control seemed to increase.6,17 CSII treatment only temporarily improved metabolic control for the first two years.1523 However, modern treatment regimens, particularly CSII, have a positive effect on the rate of hypoglycaemia18 and may be a useful tool in the treatment of nocturnal hypoglycaemia and the dawn and dusk phenomena.

Therefore, intensified therapy and a higher flexibility did not fulfil all expectations when the new treatment schemes were started. Other factors apart from the type of insulin, the therapy regimen or the way the insulin is applied seem to contribute to the success or failure of diabetes management. Such factors may be psychological or social: psychiatric disorders are associated with a higher rate of diabetic ketoacidosis,27 poorer dietary self-care and being female were predictive of poorer glycaemic control,28 and lower HbA1c was associated with lower impact, fewer worries, greater satisfaction and better health perception.29 Girls and patients from ethnic minorities had a significantly lower quality of life.29 The maternal environment also plays a major role in diabetes management, particularly in the treatment of younger children. Financially stable mothers with coping resources felt more confident in managing their child’s diabetes, and the mothers who were consistent in their diabetes management behaviours had children with better metabolic control.30

Although HbA1c levels remain too high and do not reach the levels recommended by the DCCT or ISPAD, the intensification of diabetes management over the last 30 years has resulted in significantly reduced rates of retinopathy and nephropathy in children and adolescents with type 1 diabetes, as demonstrated in the Linköpping studies.31 Therefore, we need to continue intensive diabetes treatment delivered by a multidisciplinary team that consists of intensive training of the patients and their family, individually tailored insulin treatment and the recognition of and response to possible psychological or social implications.

Article Information:

References

  1. The diabetes control and complication trial research group. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 1993;329:977–86.
  2. Swift PGF, Diabetes education (ISPAD clinical practice consensus guidelines 2006–2007), Pediatr Diabetes, 2007;8:103–9.
  3. Rewers M, Pihoker C, Donaghue K, et al., Assessment and monitoring of glycemic control in children and adolescents with diabetes (ISPAD clinical practice consensus guidelines 2006–2007), Pediatr Diabetes, 2007;8:408–18.
  4. Bulsara MK, Arcy CD, Holman J, et al., The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes, Diabetes Care, 2004;27:2293–8.
  5. Svensson J, Johannesen J, Mortensen HB, Nordly S, on behalf of the Danish Childhood Diabetes Registry. Improved metabolic outcome in a Danish diabetic paediatric population aged 0–18 yr: results from a nationwide continuous registration, Pediatr Diabetes, 2008;9:2–7.
  6. Danne T, Lange K, Kordonouri O, New developments in the treatment of type 1 diabetes in children, Arch Dis Child, 2007;92:1015–19.
  7. Holl RW, Grabert M, Schweiggert F, Heinze E, A computer program for prospective documentation of pediatric patients with type 1 diabetes mellitus, Diabetes und Stoffwechsel, 1993;3:3232–8.
  8. Kapellen TM, Wolf J, Rosenbauer J, et al., for the DPVScience- Initiative. Changes in the use of analogue insulins in 37206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years, Exp Clin Endocrinol, 2009;117(7):329–35.
  9. De Beaufort CE, Swift PGF, Skinner CT, et al., Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome?, Diabetes Care, 2007;30:2245–50.
  10. Cardwell CR, Patterson CC, Allen M, Carson DJ, Diabetes care provision and glycaemic control in Northern Ireland: a UK regional audit, Arch Dis Child, 2005;90:468–73.
  11. Scottish study group for the care of the young diabetic. Factors influencing glycemic control in young people with type 1 diabetes in Scotland, Diabetes Care, 2001;24: 239–44.
  12. Wiegand S, Raile K, Reinehr T, et al., On behalf of the DPVWiss study group. Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy, Eur J Endocrinol, 2008;158:543–9.
  13. Knerr I, Hofer SE, Holterhus PM, et al., Prevailing therapeutic regimes and predicting factors for prandial insulin substitution in 26687 children and adolescents with type 1 diabetes in Germany and Austria, Diabet Med, 2007;24:1478–81.
  14. Jeiter K, Horvath K, Berghold A, et al., Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis, Diabetologia, 2008;51:941–51.
  15. Dorchy H, Roggemans MP, Willems D, Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: a Belgian experience, Diabetes Care, 1997;20:2–6.
  16. Danne T, Mortensen HB, Hougaard P, et al., Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3805 children and adolescents with type 1 diabetes from the Hvidore study group, Diabetes Care, 2001;24:1342–7.
  17. Gerstl E, Rabl W, Rosenbauer J, et al., Metabolic control as reflected by HbA1c in children, adolescents, and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27035 patients from 207 centers in Germany and Austria during the last decade, Eur J Pediatr, 2008;167:447–53.
  18. Jakisch BI, Wagner VM, Heidtmann B, et al., Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years, Diabet Med, 2008;25:80–85.
  19. Amin R, Ross K, Acerini CL, et al., Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system, Diabetes Care, 2003;26:662–7.
  20. Pickup JC, Renard E, Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes, Diabetes Care, 2008;31(Suppl. 2):S140–S145.
  21. Fatourechi MM, Kudva YC, Murad MH, et al., Hypoglycemia with intensive insulin therapy: a systematic review and meta-analysis of randomized trials of continuous subcutaneous insulininfusion versus multiple daily injections, J Clin Endocrinol Metab, 2009;94: 729–40.
  22. Pickup JC, Sutton AJ, Severe hypoglycaemia and glycemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion, Diab Med, 2008;25:765–74.
  23. Stachow R, Wolf J, Kromeyer-Hauschild K, et al., Übergewicht und Adipositas bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 Prävalenz und Einflußfaktoren, Monatsschrift für Kinderheilkunde, 2003;151: 194–201.
  24. Mortensen HB, Robertson KJ, Aanstood HJ, et al., Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries, Diabet Med, 1998;15:752–9.
  25. Craig ME, Handelsman P, Donaghue KC, et al., for the NSW/ACT HbA1c study group, MJA, 2002;177:235–8.
  26. Reinehr T, Holl RW, Roth CL, et al., Insulin resistance in children and adolescents with type 1 diabetes mellitus: relation to obesity, Pediatr Diabetes, 2005;6:5–12.
  27. Rewers A, Chase HP, Mackenzie T, et al., Predictors of acute complications in children with type 1 diabetes, JAMA, 2002;287:2511–18.
  28. Skinner TC, Hampson SE, Personal models of diabetes in relation to self-care, well-being, and glycemic control, Diabetes Care, 2001;24:828–33.
  29. Hoey H, Aanstood HJ, Chiarelli F, et al., Good metabolic control is associated with better quality of life in 2101 adolescents with type 1 diabetes, Diabetes Care, 2001;24: 1923–8.
  30. Marvicsin D, School-age children with diabetes: role of maternal self-efficacy, environment, and management behaviors, Diabetes Educator, 2008;34:477–83.
  31. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J, Linköping Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes, Diabetologia, 2004;47:1266–72.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72